BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15457132)

  • 1. AK37: the first pyridoacridine described capable of stabilizing the topoisomerase I cleavable complex.
    Marshall KM; Holden JA; Koller A; Kashman Y; Copp BR; Barrows LR
    Anticancer Drugs; 2004 Oct; 15(9):907-13. PubMed ID: 15457132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of strong DNA-intercalating bioreductive compounds with topoisomerases I and II.
    Rosenzweig HS; Papadopoulou MV; Bloomer WD
    Oncol Res; 2005; 15(4):219-31. PubMed ID: 17822282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
    Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
    Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
    McDonald LA; Eldredge GS; Barrows LR; Ireland CM
    J Med Chem; 1994 Oct; 37(22):3819-27. PubMed ID: 7525959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives.
    Nabiev I; Chourpa I; Riou JF; Nguyen CH; Lavelle F; Manfait M
    Biochemistry; 1994 Aug; 33(30):9013-23. PubMed ID: 8043587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
    Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
    Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-a]indole derivatives and their growth inhibitory activities.
    Umemura K; Mizushima T; Katayama H; Kiryu Y; Yamori T; Andoh T
    Mol Pharmacol; 2002 Oct; 62(4):873-80. PubMed ID: 12237334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
    Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
    Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory properties of antitumor prostaglandins against topoisomerases.
    Suzuki K; Uyeda M
    Biosci Biotechnol Biochem; 2002 Aug; 66(8):1706-12. PubMed ID: 12353631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine.
    Marshall KM; Matsumoto SS; Holden JA; Concepción GP; Tasdemir D; Ireland CM; Barrows LR
    Biochem Pharmacol; 2003 Aug; 66(3):447-58. PubMed ID: 12907244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex.
    Constantinou AI; Husband A
    Anticancer Res; 2002; 22(5):2581-5. PubMed ID: 12529967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro.
    Constantinou A; Stoner GD; Mehta R; Rao K; Runyan C; Moon R
    Nutr Cancer; 1995; 23(2):121-30. PubMed ID: 7644381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
    Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
    Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
    Suzuki H; Ikeda T; Yamagishi T; Nakaike S; Nakane S; Ohsawa M
    Mutat Res; 1995 May; 328(2):151-61. PubMed ID: 7739599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
    My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
    Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
    Yao BL; Mai YW; Chen SB; Xie HT; Yao PF; Ou TM; Tan JH; Wang HG; Li D; Huang SL; Gu LQ; Huang ZS
    Eur J Med Chem; 2015 Mar; 92():540-53. PubMed ID: 25599951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 2-phenol-4-chlorophenyl-6-aryl pyridines as topoisomerase II inhibitors and cytotoxic agents.
    Thapa P; Kadayat TM; Park S; Shin S; Thapa Magar TB; Bist G; Shrestha A; Na Y; Kwon Y; Lee ES
    Bioorg Chem; 2016 Jun; 66():145-59. PubMed ID: 27174797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in silico assessment of DNA interaction, topoisomerase I and II inhibition properties of chrysosplenetin.
    Şöhretoğlu D; Barut B; Sari S; Özel A; Arroo R
    Int J Biol Macromol; 2020 Nov; 163():1053-1059. PubMed ID: 32673727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.